Genomics

Dataset Information

0

RNA-seq analysis of gene regulations by the combination treatment of crizotinib plus cisplatin in established MCA205 tumors


ABSTRACT: Immunogenic cell death (ICD) converts dying cancer cells into a therapeutic vaccine and stimulates antitumor immune responses. Here we unravel the results of an unbiased screen identifying high-dose (10 µM) crizotinib as an ICD-inducing tyrosine kinase inhibitor that has exceptional antineoplastic activity when combined with non-ICD inducing chemotherapeutics like cisplatin. The combination of cisplatin and high-dose crizotinib induces ICD in non-small cell lung carcinoma (NSCLC) cells and effectively controls the growth of distinct (transplantable, carcinogen- or oncogene induced) orthotopic NSCLC models. These anticancer effects are linked to increased T lymphocyte infiltration and are abolished by T cell depletion or interferon-g neutralization. Crizotinib plus cisplatin leads to an increase in the expression of PD-1 and PD-L1 in tumors, coupled to a strong sensitization of NSCLC to immunotherapy with PD-1 antibodies. Hence, a sequential combination treatment consisting in conventional chemotherapy together with crizotinib, followed by immune checkpoint blockade may be active against NSCLC.

ORGANISM(S): Mus musculus

PROVIDER: GSE126988 | GEO | 2019/02/25

REPOSITORIES: GEO

Similar Datasets

| E-GEOD-62118 | biostudies-arrayexpress
2020-12-19 | GSE149215 | GEO
2021-10-31 | GSE186767 | GEO
| E-MTAB-13704 | biostudies-arrayexpress
2023-07-31 | GSE239666 | GEO
2023-08-29 | PXD041782 | Pride
| E-GEOD-62663 | biostudies-arrayexpress
2022-10-06 | GSE214715 | GEO
2014-10-07 | GSE62118 | GEO
2017-04-25 | GSE93124 | GEO